ONDANSETRON ORAL DISPERSIBLE FILM CARES FOR CANCER PATIENTS

More effective cancer treatments mean that greater numbers of patients are living with cancer, but also that they need appropriate support to manage their illness, the adverse effects of therapies and the emotional burden of the disease.
With the validation of the Health Education Impact Questionnaire, support services are now able to measure the impact of their programs on patients’ sense of empowerment (Maunsell E, et al. Cancer 2014, published online: 2 JUL 2014, DOI: 10.1002/cncr. 28847 and Lauzier S, et al. Cancer 2014, published online: 2 JUL 2014, DOI: 10.1002/cncr.28846).
Ondansetron Oral Dispersible Film, effective in the prevention/treatment of chemotherapy and radiotherapy induced nausea and vomiting, has a major market share in European countries and sales are expected to grow with increasing patient numbers.
Ondansetron Oral Dispersible Film (ODF) was the first prescription product with full pediatric indications to be registered in Europe thanks to its specific drug delivery system and dosage form.
APR offers marketing and commercialization rights for Ondansetron ODF through regional or local license agreements.
2014-12-23T10:28:30+00:00 Applied Pharma Research (APR)